Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection

– Turletricin Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA –

– Elion to Present Turletricin Clinical Data at ESCMID Global –

Excerpt from the Press Release:

BOSTON, April 15, 2026 (GLOBE NEWSWIRE) — Elion Therapeutics, a biotechnology company dedicated to transforming the treatment of life-threatening fungal infections, today announced the initiation of its Phase 2 clinical trial evaluating turletricin (study drug EL219) early antifungal therapy in study participants with suspected and confirmed invasive mould infection (“TREAT-1”). Invasive mould infection (IMI) can cause severe or life-threatening illness in study participants with weakened immune systems, and early treatment is critical for improved patient outcomes.

“The QIDP designation and initiation of the TREAT-1 study, with its novel design, represents a key milestone for turletricin and underscores its distinctive potential as a once-weekly, broad-spectrum, non-nephrotoxic polyene antifungal used early in people with suspected IMI,” said Dr. Kieren Marr, CEO of Elion Therapeutics. “Because delayed antifungal therapy is associated with poor outcomes in those who lack adequate immune responses, we are eager to progress enrollment towards demonstrating the potential advantages of weekly turletricin compared to the current standard of care.”

The Phase 2 global TREAT-1 clinical trial is a multicenter, randomized, double-blind study evaluating the safety and efficacy of turletricin versus standard of care for early antifungal therapy in study participants with suspected and confirmed IMI.

Click the button below to read the entire Press Release:

Continue Reading The Press Release